Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 23 of 80 for:    "Adult Acute Lymphocytic Leukemia" | "Antineoplastic Agents, Hormonal"

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02043587
Recruitment Status : Active, not recruiting
First Posted : January 23, 2014
Last Update Posted : October 19, 2018
Sponsor:
Collaborator:
Leadiant Biosciences, Inc.
Information provided by (Responsible Party):
Matthew Wieduwilt, M.D., Ph.D., University of California, San Diego

Brief Summary:
The objective of this protocol is to improve survival for adults with acute lymphoblastic leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis.

Condition or disease Intervention/treatment Phase
Acute Lymphocytic Leukemia Adult Lymphoblastic Lymphoma Drug: DNR Drug: VCR Drug: PEG-asp Drug: CTX Drug: Prednisone Drug: Liposomal AraC Drug: MTX Drug: LCV Drug: AraC Drug: Etoposide Drug: Dasatinib Drug: Rituximab Drug: Hydrocortisone Phase 2

Detailed Description:

This treatment regimen builds on the "Linker" regimen/UCSF Protocol 8707 ALL regimen backbone with the goal of improved efficacy and acceptable toxicity by substituting pegylated asparaginase for native L-asparaginase, the addition of rituximab for pre-B-cell ALL, and the addition of dasatinib for Philadelphia chromosome/BCR-ABL positive ALL, and the addition of cyclophosphamide for younger adults. In addition, the study regimen aims to reduce CNS relapse through the use of intrathecal liposomal cytarabine in place of intrathecal methotrexate for CNS relapse prophylaxis and

The regimen uses 3 modules of therapy with non-cross-resistant chemotherapy agents. Rituximab is added for a total of 8 doses for patients with pre-B-cell ALL. Dasatinib is added for patients with Ph+ ALL.

Course 1A (Induction): Daunorubicin, vincristine, PEG-asparaginase, and prednisone for all patients with the addition of cyclophosphamide for patients 18-39 years of age. Treatment is intensified for patients with disease present on a day 14 bone marrow biopsies during Induction Course 1A. In addition to standard analyses, minimal residual disease will be assessed on day 14 and remission bone marrow aspirates and correlated with outcomes.

Course 1B: High-dose methotrexate, oral 6-mercaptopurine, and PEG-asparaginase.

Course 1C: High-dose cytarabine and etoposide.

The 3 courses then repeat (2A (Intensification), 2B, 2C) followed by a final "B" cycle (3B) of high-dose methotrexate, 6-mercaptopurine, and PEG-asparaginase.

After completion of Course 3B, patients proceed to maintenance chemotherapy with monthly methotrexate, vincristine, 6-mercaptopurine, and prednisone cycles for 24 months with a single dose PEG-asparaginase given in month 1 of Maintenance.

CNS prophylaxis: Intrathecal liposomal cytarabine replaces intrathecal methotrexate CNS prophylaxis and is given every 2 weeks during the "A" Induction and Intensification courses then every 3 months during Maintenance for a total of 8 doses. Given the presence of CNS penetrating chemotherapy in the "B" and "C" cycles, intrathecal liposomal cytarabine is not given due to risk of excessive CNS toxicity.

There is a randomization to hydrocortisone or placebo premedication prior to PEG-asparaginase.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Study Start Date : January 2014
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020


Arm Intervention/treatment
Experimental: Chemotherapy for ALL

Course 1A: DNR 60 mg/m2 IV d1,2,3; VCR 1.4 mg/m2 d1,8,15,22 (cap 2 mg age >50); PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3750 IU/m2; CTX 750 mg/m2 d1,15 age < 40; Prednisone 60 mg/m2 PO d1-28; Liposomal AraC 25 mg IT d1, 15

1B: MTX 220 mg/m2 IV then 60 mg/m2/h for 36h d2-3,d16-17; LCV 50 mg/m2 IV q6h x3 then 10 mg/m2 PO/IV q6h til MTX <0.1 uM; 6-MP 60 mg/m2 PO d2-8, d16-22; PEG-asp 2000 IU/m2 IV d18, age >50 1000 IU/m2, cap 3750 IU/m2

1C: AraC 2 g/m2 IV d1-4; Etoposide 500 mg/m2 IV d1-4

1A-C repeat x1(2A-C) then 3rd Course B (3B)

Maintenance (monthly, 24 mo): Prednisone 60 mg/m2 PO d1-5; VCR 1.4 mg/m2 IV d1 (cap 2 mg age >50); MTX 20 mg/m2 PO wkly; 6-MP 60 mg/m2 PO qd PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3,750 IU/m2 (Mo. 1)

Maintenance mo. 1-4: Liposomal AraC 50 mg IT d1

Dasatinib 140 mg PO qd if Ph/BCR-ABL+; Rituximab 375 mg/m2 IV d1,15 of 1A-C, 2A (Pre-B)

1:1 randomization: hydrocortisone v. placebo before PEG-asp 1B, 2B, & Maint.

Drug: DNR
Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
Other Names:
  • Daunorubicin
  • Daunorubicin Hydrochloride
  • Cerubidine
  • Daunomycin
  • Rubidomycin

Drug: VCR
1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages >50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
Other Names:
  • Vincristine
  • Oncovin
  • Vincasar
  • PFS
  • Vincrex
  • Leurocritine
  • LCR

Drug: PEG-asp
2,000 IU/m2 IV for ages </= 50, age > 50, 1000 IU/m2 IV Day 16, Courses 1A & 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
Other Names:
  • PEG-L-asparaginase
  • Oncaspar
  • PEG-asparaginase
  • pegasparagase

Drug: CTX
750 mg/m2 IV, days 1 &15 for subjects <40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 & 16 for subjects < 40 years of age if day 14 bone marrow M2 or M3; Courses 1A & 2A
Other Names:
  • Cyclophosphamide
  • Cytoxan
  • Endoxan
  • Neosar
  • Procytox
  • Revimmune
  • cytophosphane
  • CPM
  • CYT

Drug: Prednisone
60 mg/m2 orally once daily on days 1-28 during Courses 1A & 2A; Maintenance: Monthly, days 1-5
Other Name: Deltasone

Drug: Liposomal AraC
25 mg intrathecal (IT), on days 1 & 15 during Courses 1A & 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
Other Names:
  • Liposomal cytarabine
  • DepoCyt

Drug: MTX
220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B & 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
Other Names:
  • Methotrexate
  • Rheumatrex
  • Trexall

Drug: LCV
50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B & 2B
Other Name: Leucovorin

Drug: AraC
2,000 mg/m2 IV, days 1-4 during Courses 1C & 2C
Other Names:
  • Cytarabine
  • Ara-C
  • Arabinosylcytosine
  • Cytosar-U

Drug: Etoposide
500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C & 2C
Other Names:
  • VP-16
  • VePesid
  • Toposar

Drug: Dasatinib
140 mg orally daily if BCR/ABL positive and/or Ph+
Other Name: Sprycel

Drug: Rituximab
375 mg/m2 IV once daily on days 1 & 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C & 2A
Other Name: Rituxan

Drug: Hydrocortisone
Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
Other Names:
  • Hydrocortisone sodium succinate
  • Solu-Cortef




Primary Outcome Measures :
  1. Event-free survival [ Time Frame: 3-year ]

Secondary Outcome Measures :
  1. Liposomal cytarabine toxicity [ Time Frame: 3 years ]
  2. CNS relapse rate [ Time Frame: 3-year ]
  3. Overall survival [ Time Frame: 3-year ]
  4. Leukemia-free survival [ Time Frame: 3-year ]
  5. Efficacy of hydrocortisone premedication for reduced PEG-asparaginase allergic reactions [ Time Frame: 3 years ]
  6. PEG-asparaginase toxicities [ Time Frame: 3 years ]
  7. Complete and overall response rates [ Time Frame: 3 years ]
  8. Non-relapse mortality [ Time Frame: 3-year ]

Other Outcome Measures:
  1. Minimal residual disease and outcomes [ Time Frame: 3 years ]
  2. Asparaginase antibodies and asparaginase activity [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to understand and the willingness to sign a written informed consent.
  • Diagnosis of acute lymphoblastic leukemia or lymphoblastic lymphoma as defined by the World Health Organization [94]
  • Untreated disease EXCEPT for corticosteroids, hydroxyurea, leukapheresis, and/or tyrosine kinase inhibitors for up to 2 weeks prior to initiation of study therapy.
  • Age 18 through 60 years
  • ECOG performance status 0,1, or 2 (see Appendix A)
  • Adequate organ function defined as:
  • Total bilirubin < 2 mg/dL (unless due to ALL)
  • AST(SGOT)/ALT(SGPT) < 3 times institutional upper limit of normal (unless due to ALL)
  • Serum creatinine < 2 mg/dL (unless elevated creatinine felt by investigator to be acute and reversible) OR creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
  • Left ventricular ejection fraction ≥50%
  • Women of child-bearing potential and men with partners of child- bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)

Exclusion Criteria:

  • Current or anticipated use of other investigational agents during the study
  • Known central nervous system mass lesion
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to liposomal cytarabine or other agents used in study inclusive of known allergy to polyethylene glycol.
  • History of unprovoked venous thrombosis/thromboembolism
  • Recurrent or chronic pancreatitis
  • Uncontrolled diabetes mellitus
  • Uncontrolled intercurrent illness that would limit compliance with study requirements including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or nursing.
  • Any condition, in the opinion of the investigator, that compromises compliance with study requirements
  • Known HIV positivity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02043587


Locations
Layout table for location information
United States, California
UCSD, Division of Blood and Marrow Transplantation, Moores Cancer Center
La Jolla, California, United States, 92093
Hematological Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine at UCLA
Los Angeles, California, United States, 90095
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817
UCSF Comprehensive Cancer Center
San Francisco, California, United States, 94143-0324
Sponsors and Collaborators
University of California, San Diego
Leadiant Biosciences, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Matthew J Wieduwilt, MD, PhD UC San Diego, Division of Blood and Marrow Transplantation

Publications of Results:
Layout table for additonal information
Responsible Party: Matthew Wieduwilt, M.D., Ph.D., Assistant Clinical Professor, University of California, San Diego
ClinicalTrials.gov Identifier: NCT02043587     History of Changes
Other Study ID Numbers: 130934
First Posted: January 23, 2014    Key Record Dates
Last Update Posted: October 19, 2018
Last Verified: October 2018
Keywords provided by Matthew Wieduwilt, M.D., Ph.D., University of California, San Diego:
Acute lymphoblastic leukemia
Lymphoblastic leukemia
Lymphoblastic lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents, Hormonal
Lymphoma
Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Cytarabine
Prednisone
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Cyclophosphamide
Rituximab
Methotrexate
Etoposide
Dasatinib
Daunorubicin
Asparaginase
Pegaspargase
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents